LANGaware Forges Transformative Collaboration with Premier, Inc.'s PINC AI™ Applied Sciences (PAS) to Revolutionize Healthcare

Rhea-AI Summary

LANGaware partners with Premier's PINC AI™ Applied Sciences to leverage Real-World Data (RWD) for the development of novel therapeutics addressing neurodegenerative and behavioral health diseases. The collaboration aims to support early patient identification and detection, improve quality, lower costs, reduce risk, and ensure safety for patients. LANGaware's AI-driven precision in early detection reduces the likelihood of false positives and unnecessary treatments, with the goal of revolutionizing early detection of cognitive and mental health diseases and driving positive changes in the healthcare industry.

Medical Research Analyst

The partnership between LANGaware and PINC AI™ Applied Sciences leverages a growing trend in healthcare to utilize Real-World Data (RWD) for the advancement of therapeutic strategies. This collaboration has the potential to enhance patient outcomes by enabling earlier identification and intervention in neurodegenerative and behavioral health diseases. RWD, which includes information collected from various sources outside of traditional clinical research settings, can provide a more comprehensive view of patient health and treatment efficacy in real-world scenarios.

From a research perspective, the use of retrospective synthetic arms constructed from extensive databases can accelerate the research process and reduce costs by minimizing the need for traditional, prospective clinical trials. This method can also improve the generalizability of research findings to broader patient populations. However, the quality of RWD is paramount and the methodologies for collecting and analyzing such data must be rigorous to ensure reliability and validity.

Healthcare Economist

The economic implications of this partnership could be substantial, particularly in the realm of healthcare cost savings. Early detection of diseases like Alzheimer's and depression has the potential to reduce the long-term costs associated with chronic disease management by shifting the focus towards prevention and early intervention. This shift can lead to a decrease in hospitalizations, less need for intensive long-term care and a reduction in the use of high-cost pharmaceuticals.

Additionally, the healthcare industry often faces challenges in adopting new technologies due to cost constraints. However, the potential for RWD to lower research and development expenses could make innovative diagnostics more accessible and cost-effective for health systems. This could drive market competition and incentivize further innovation in the sector, ultimately benefiting patients and stakeholders alike.

Market Research Analyst

The strategic alliance between LANGaware and PINC AI™ Applied Sciences is indicative of the increasing value placed on partnerships in the biotechnology and healthcare industries. By combining LANGaware's AI-driven diagnostic tools with PINC AI's extensive healthcare database, the partnership is poised to capture a significant share of the market for early detection technologies. As the demand for personalized medicine and precision healthcare grows, companies that offer innovative solutions for early diagnosis and treatment are well-positioned to capitalize on emerging market opportunities.

Investors and stakeholders in the healthcare sector should monitor the outcomes of such partnerships closely, as they can signal shifts in industry standards and practices. Successful implementation and integration of RWD into clinical decision-making could serve as a model for other companies looking to innovate in this space, potentially influencing stock valuations and investment trends within the sector.

Real-world data to support early patient identification for patients with neurodegenerative and behavioral health diseases.

NEW YORK, Jan. 24, 2024 /PRNewswire/ -- LANGaware, an innovative leader in digital cognitive and behavioral health diagnostics, is announcing that it will partner with Premier's (NASDAQ: PINC) PINC AI™ Applied Sciences (PAS) to leverage Real-World Data (RWD) for the development of novel therapeutics addressing neurodegenerative and behavioral health diseases.

PAS, renowned for its robust data gleaned from over 4,350 hospitals and 300,000 continuum-of-care providers nationwide, will provide expertise in conducting prospective research utilizing retrospective synthetic arms built from the PINC AI™ Healthcare Database (PHD). 

"Neurodegenerative diseases like Alzheimer's and Parkinson's and behavioral health conditions such as depression affect millions of people worldwide," said Denise Juliano, Group Vice President of Life Sciences at PINC AI™ Applied Sciences. "The PAS-LANGaware partnership will enable RWD that supports early patient identification and detection – and drives evidence-based decisions by clinicians to improve quality, lower costs, reduce risk and help ensure safety for these patients."

LANGaware, known for its AI-driven precision in early detection, aims to extend the availability of its platform to individuals, health systems and life science companies. Through unique voice and language biomarkers, LANGaware's technology reduces the likelihood of false positives and unnecessary treatments.

"We are thrilled to partner with PAS and extend the reach of our digital assessment tool to more patients, health systems and life science companies," said Vassiliki Rentoumi, Founder and CEO of LANGaware. "Our goal is to revolutionize early detection of cognitive and mental health diseases, supporting novel therapy development as well as earlier intervention by providers, to improve patient outcomes and drive positive changes in the healthcare industry. We are actively seeking partners that share our commitment to transforming patient care."

The collaboration signifies a significant step forward in expanding access to advanced diagnostic services across the United States. By combining PAS' extensive network of health systems and PINC AI's RWD capabilities with LANGaware's cutting-edge technology, the partnership aims to revolutionize healthcare by driving innovation in early detection and treatment.

About LANGaware
LANGaware is a pioneering company that leverages AI technology to revolutionize cognitive and mental health diagnostics. By utilizing speech analysis and proprietary voice and speech biomarkers, LANGaware provides early and objective detection of conditions, enabling more effective treatments, reducing healthcare burdens, and improving overall well-being. The company's vision is to transform the healthcare industry by seamlessly integrating AI-driven diagnostic tools and empowering healthcare professionals with valuable insights for personalized care. For more information, please visit LANGaware's In the News on www.langaware.com; as well as Twitter, LinkedIn, and LANGaware's blog for more information about the company.

About PINC AI™ Applied Sciences (PAS)
PAS is a trusted leader in accelerating healthcare improvement through services, data and scalable solutions, spanning the continuum of care and enabling sustainable innovation and rigorous research. These services and RWD are valuable resources for the pharmaceutical, device and diagnostic industries, academia, federal and national healthcare agencies, as well as hospitals and health systems. Since 2000, PAS researchers have produced more than 1,000 publications which appear in 264 scholarly, peer-reviewed journals, covering a wide variety of topics, and conduct population-based analyses of drugs, devices, treatments, disease states, epidemiology, resource utilization, healthcare economics and clinical outcomes.

About the PINC AI™ Platform
PINC AI^™ is the technology and services platform of Premier, Inc. (NASDAQ: PINC). With more than 20 years' worth of cost, quality and operational data gleaned from 45 percent of U.S. hospital discharges, 2.7 billion hospital outpatient and clinic encounters and 177 million physician office visits, the PINC AI^™ platform provides actionable intelligence to help improve outcomes, support improved financial performance and enable success in new, alternative payment models. PINC AI^™ offerings and capabilities can be followed on Twitter and LinkedIn.

Premier, Inc. Forward-Looking Statements
This press release includes statements about Premier and PINC AI™ and the use of their products and services that are not statements of historical or current facts and are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause performance or achievements relating to Premier and PINC AI products and services to be materially different from any future results or projections expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. More information on potential risk factors relating to Premier and PINC AI is included from time to time in the "Cautionary Note Regarding Forward-Looking Statements," "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Premier's periodic and current filings with the SEC, which are also made available on Premier's website at investors.premierinc.com.

Media Contacts:
Virginia Korma	Sarah Flora
646-878-9063	913-683-4015
virginia@langaware.com	sarah@langaware.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/langaware-forges-transformative-collaboration-with-premier-incs-pinc-ai-applied-sciences-pas-to-revolutionize-healthcare-302040964.html

SOURCE LANGaware

What is the partnership announced in the PR?

The partnership is between LANGaware and Premier's PINC AI™ Applied Sciences to leverage Real-World Data (RWD) for the development of novel therapeutics addressing neurodegenerative and behavioral health diseases.

What is the goal of LANGaware's technology?

LANGaware's technology aims to revolutionize early detection of cognitive and mental health diseases, supporting novel therapy development and earlier intervention by providers to improve patient outcomes.

What is the significance of the collaboration?

The collaboration signifies a significant step forward in expanding access to advanced diagnostic services across the United States, aiming to revolutionize healthcare by driving innovation in early detection and treatment.